By InvitationPhase 1/2

Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

Russia22 participantsStarted 2024-09-01

Plain-language summary

Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age from 0 years to 17 years 11 months * Established on the basis of histological and immunohistochemical studies, the diagnosis of PMLBL (the presence of programmed death-ligand on tumor cells is not necessary) * Lack of specific therapy for lymphoma * Signed informed consent Exclusion Criteria: * Age \>18 * History of specific therapy for lymphomas. * Drug intolerance

What they're measuring

Event free survival

Timeframe: 5 year

Trial details

NCT IDNCT06871007

SponsorSt. Petersburg State Pavlov Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-09-01

View on ClinicalTrials.gov More Primary Mediastinal (Thymic) Large B-cell Lymphoma trials